TLDR: On October 28, 2026, the U.S. Food and Drug Administration exercised enforcement discretion for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. According to NBC News reporting on the HHS notice, licensed compounding pharmacies can now prepare these peptides while FDA completes formal rulemaking for the 503A Bulks List. None of the six are FDA-approved, and access requires a valid prescription and medical supervision. Profusions connects eligible patients with licensed providers for evaluation of peptide therapy, GLP-1 care with semaglutide and tirzepatide, sermorelin, NAD+, and TRT.
Peptide access in the United States changed this week. After restrictions that limited compounding since 2023, federal health officials restored a legal path for patients to obtain six specific peptides through licensed pharmacies with a prescription.
This update explains what the FDA decision to restore access to six peptides actually means, which compounds are included, what safety rules still apply, and how to pursue peptide therapy without turning to the gray market.
FDA Restores Access to Six Peptides Through Enforcement Discretion
The Department of Health and Human Services filed a notice on October 28, 2026 stating it will exercise enforcement discretion for six peptides. In practice, that means FDA will not take legal action against compounding pharmacies that prepare them, even though formal addition to the FDA bulk drug substances list is still pending.
The six peptides covered are:
- BPC-157
- Epitalon
- KPV
- MOTS-c
- Semax
- TB-500
These six were the subject of a July 2026 FDA advisory committee vote in favor of adding them to the 503A Bulks List. As legal analysis from Holland and Knight and Buchanan Ingersoll notes, an advisory vote alone does not place an ingredient on the list. Full rulemaking with proposal, public comment, and final rule is still required. Enforcement discretion bridges that gap.
Two important limits apply. First, this is temporary. FDA continues to weigh formal rulemaking, with no published deadline. Second, none of these peptides are FDA-approved. FDA scientists previously concluded there is insufficient data to prove safety and effectiveness, which is why the agency now requires compounding pharmacies to certify identity and purity and to report side effects.
Why Licensed Pharmacy Access Matters More Than Gray Market Peptides
As access returns, both HHS and clinical pharmacy groups urge the same caution: obtain peptides only through a licensed compounding pharmacy with a valid prescription.
The EVEXIAS and FarmaKeio announcement warns that products sold online as research use only or not for human consumption do not meet pharmacy standards for quality, sterility, and testing. Those products may be adulterated, sub-potent or super-potent, and carry additional health risks.
Licensed 503A compounding pharmacies operate under a different standard:
- State licensure and FDA registration where required
- Verified active pharmaceutical ingredients with Certificates of Analysis
- Sterile processing controls for injectables, including USP 797 compliance
- Batch testing for identity, purity, sterility, and endotoxins
- New FDA requirement to report adverse events for these six peptides
This distinction is central to Profusions care. Prescriptions are issued only after review by a licensed provider, and compounded medications are dispensed by state-licensed U.S. partner pharmacies, including PCAB-accredited and LegitScript-compliant facilities. Profusions does not source from research chemical sellers.
Patients already in Profusions peptide programs, including sermorelin therapy and NAD+ support, continue under the same medical supervision model. Eligibility, dosing, and monitoring are individualized. BPC-157 availability, where clinically appropriate and permitted, will follow the same prescription and pharmacy pathway, not over-the-counter sale.
What This Means If You Are Considering Peptide Therapy
Restored access does not mean every patient is a candidate. A licensed provider still must evaluate health history, current medications, contraindications, and goals before prescribing.
A responsible telehealth evaluation for peptides includes:
- Comprehensive intake and review of medical history
- Baseline labs where clinically indicated
- Discussion of benefits, risks, and alternatives
- Individualized dosing and titration plan
- Follow-up messaging and monitoring for side effects
Many patients explore peptides alongside broader metabolic and hormone care. Profusions offers medically supervised GLP-1 programs with compounded semaglutide and compounded tirzepatide, sermorelin peptide therapy, subcutaneous NAD+ therapy, and testosterone replacement therapy for men with documented deficiency. Your provider can determine whether a peptide, a metabolic program, hormone optimization, or a combination fits your profile.
To start a confidential evaluation with a licensed provider in your state, visit https://www.myprofusions.com/get-started/.
Profusions Health and Wellness is a virtual telehealth clinic. Prescription required. Compounded medications, including peptides, are prepared by state-licensed pharmacies pursuant to a patient-specific prescription and are not FDA-approved finished products. BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 are not FDA-approved, and FDA has stated that safety and effectiveness data remain insufficient. This article is educational and is not medical advice. Individual results vary. Always consult a licensed healthcare provider.
